<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466176</url>
  </required_header>
  <id_info>
    <org_study_id>BECRO/RESP/BE250-PIVOTAL</org_study_id>
    <nct_id>NCT04466176</nct_id>
  </id_info>
  <brief_title>A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers</brief_title>
  <official_title>A Pivotal, Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respirent Pharmaceuticals Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BECRO Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Respirent Pharmaceuticals Co Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence study between two inhaler products of fixed dose combination of fluticasone
      propionate and salmeterol xinafoate inhalation powder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A bioequivalence study of a single dose of the fixed-dose combination of fluticasone
      propionate and salmeterol xinafoate inhalation powder administered from Fluticasone
      propionate 250 mcg and Salmeterol xinafoate 50 mcg inhalation powder/Respirent
      Pharmaceuticals (test-Τ) as 2 inhalations and ADVAIR DISKUS® 250/50 mcg inhalation powder/GSK
      (reference-R) in healthy volunteers under fasting conditions. The study will be one-center
      crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>laboratory-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>Maximum plasma concentration, it is read directly from the raw data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>Area under the plasma concentration curve from time 0 to the last measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>Area under the plasma concentration-time curve extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>Time until Cmax is reached, it is read directly from the observed concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>Plasma concentration halflife, it is calculated from the ratio 0.693/λZ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>Terminal elimination rate constant, calculated from the slope of the final phase of the ln-concentration curve versus time with regression analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual area</measure>
    <time_frame>up to 36 hours post-administration</time_frame>
    <description>[AUC(0-∞)-AUC(0-t)]/AUC(0-∞)]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ADVAIR DISKUS® 250/50</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test Product</intervention_name>
    <description>2 inhalations of Test and Reference product in each study period</description>
    <arm_group_label>Test Product</arm_group_label>
    <other_name>Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference Product</intervention_name>
    <description>2 inhalations of Test and Reference product in each study period</description>
    <arm_group_label>Reference Product</arm_group_label>
    <other_name>ADVAIR DISKUS 250/50</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers of both genders, aged ≥18 and ≤60 years.

          2. Subjects with Body Mass Index (ΒΜΙ) ≥18.5 and &lt;30.0 kg/m2.

          3. Healthy volunteers are declared healthy based on medical history, physical
             examination, ECG, pulmonary function test (a forced expiratory volume in 1 second
             (FEV1) ≥80% of the predicted normal value), and clinical laboratory values within the
             laboratory stated normal range; if not within this range, they must be without any
             clinical significance according to the Investigator.

          4. Females who participate in the study are either at reproductive age i.e.pre-menopausal
             or unable to gestate [i.e. post-menopausal (absence of menses for 12 months prior to
             drug administration), hysterectomy, bilateral oophorectomy, tubal ligation at least 6
             months prior to drug administration].

          5. Subjects that are non-smokers.

          6. Subjects that, in the opinion of the principal investigator/medical officer, are able
             to communicate and comply with the study procedures and protocol restrictions as
             evidenced by the Informed Consent Form (ICF) duly read, signed and dated by the
             subject prior to study initiation.

          7. Subjects able to use the inhalers according to given instructions, as judged by the
             Investigator or study nurse.

        Exclusion Criteria:

          1. Hypersensitivity to the active substance(s) or to the excipient (lactose which
             contains small amounts of milk protein may cause allergic reactions) or related class
             (any sympathomimetic drug or any inhaled, intranasal, or systemic corticosteroid
             therapy) of the medicinal product

          2. Clinically significant illness or surgery within four weeks prior to dosing.

          3. Clinically significant ECG abnormalities or vital sign abnormalities (seated systolic
             blood pressure &lt;90 or &gt;140 mmHg, seated diastolic blood pressure &lt;50 or &gt;90 mmHg or
             heart rate less than 50 or over 100 bpm) at screening.

          4. Clinically significant history or presence of chronic bronchitis, emphysema,asthma or
             any other lung disease.

          5. History or presence of pulmonary tuberculosis.

          6. Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear
             infection within 4 weeks prior to the screening visit.

          7. History or presence of significant cardiovascular, endocrinal, neurologic,
             immunological, psychiatric or metabolic disease.

          8. History of significant alcohol or drug abuse within one year prior to the screening
             visit.

          9. Regular use of alcohol within six months prior to screening visit (more than 14
             alcohol units per week) [1Unit =150 ml of wine, 360 ml of beer, or 45 ml of 40%
             alcohol].

         10. Inability to abstain from alcohol for the duration of study period.

         11. Presence of disease markers for Hepatitis B, Hepatitis C or HIV at screening.

         12. Positive results for drugs of abuse (barbiturates, marijuana, opioids, benzodiazepines
             and methadone) in saliva before each administration.

         13. Positive alcohol breath test before each administration.

         14. Use of soft drugs (such as marijuana) within three months prior to screening or hard
             drugs such as crack, cocaine or heroin within one year prior to screening visit

         15. Intake of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers are barbiturates, carbamazepine, phenytoin, glucocorticoids,
             rifampin/rifabutin; examples of inhibitors are, erythromycin, ketoconazole, indinavir,
             cobicistat-containing products) within one month prior to administration of the study
             medication. Under these circumstances, subject inclusion will be judged by the
             principal investigator.

         16. History of peptic ulcer, other gastrointestinal disorders (e.g. chronic diarrhoea,
             irritable bowel syndrome) or unresolved gastrointestinal symptoms (e.g. diarrhea,
             vomiting) or significant hepatic, renal or other condition that is known to interfere
             with the absorption, distribution, metabolism or excretion of the drug.

         17. Use of oral or parenteral corticosteroids in the previous four 4 weeks

         18. Eye disorders especially Glaucoma (or a family history of glaucoma)

         19. Use of prescription medication (within 14 days prior to the first administration of
             study medication) or over-the-counter (OTC) products (including food supplements
             vitamins and herbal supplements) within one week (7 days) prior to the first
             administration of study medication, except for topical products without systematic
             absorption. Contraceptives are allowed.

         20. Vaccination for prophylaxis from seasonal flu or any other vaccination within seven
             days prior to administration

         21. History of allergy to any food, intolerance or special diet, that in the opinion of
             the medical sub-investigator could contraindicate the subject's participation in the
             study.

         22. A depot injection or an implant of any drug (except hormonal contraceptives) within 3
             months prior to treatment administration.

         23. Donation of plasma (500 ml) within 7 days prior to treatment administration.

         24. Donation of whole blood or loss of whole blood ≥ 500 ml prior to administration of the
             study medication within 30 days prior to treatment administration.

         25. Participation in another clinical trial simultaneously.

         26. Subjects receiving special diet or having intolerance in any of the provided study
             meals or refusing to eat the study meals

         27. Application of tattoo or body piercing within 30 days prior to treatment
             administration.

         28. Non-tolerance to venipuncture.

         29. Breastfeeding women.

         30. Positive pregnancy test at screening

         31. Females of reproductive age that had sexual intercourse with a non-sterile male
             partner without protection within 14 days prior to drug administration

        Reliable contraception methods are considered the following:

          -  combined (estrogen and progestogen containing) hormonal contraception associated with
             inhibition of ovulation: oral, intravaginal or transdermal

          -  progestogen-only hormonal contraception associated with inhibition of ovulation oral,
             implanable or injectable

          -  intrauterine device (IUD)

          -  intrauterine hormone-releasing system (IUS)

          -  bilateral tubal occlusion

          -  vasectomised partner

          -  sexual abstinence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioannis Stefanidis, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Thessaly Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BECRO Clinical Facility</name>
      <address>
        <city>Larissa</city>
        <state>Thessaly</state>
        <zip>41100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>fluticasone propionate</keyword>
  <keyword>salmeterol xinafoate</keyword>
  <keyword>ADVAIR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone-Salmeterol Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

